NCT03544047 is a NA clinical trial of Paclitaxel in Organoid, sponsored by Peking Union Medical College.

Who is sponsoring NCT03544047?

NCT03544047 is sponsored by Peking Union Medical College.

What drugs are being tested in NCT03544047?

Interventions in NCT03544047: Paclitaxel.

Is NCT03544047 still recruiting?

NCT03544047 is currently status unknown. Last updated 11 December 2018.

Last reviewed 2018-12-11 · How we verify

NCT03544047

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model

Status unknown NA Last updated 11 December 2018

What this trial tests

NA trial testing Paclitaxel in Organoid in 50 participants. Status unknown.

Timeline

1 January 2019

Primary endpoint
1 July 2020

1 July 2020

Quick facts

Lead sponsor	Peking Union Medical College
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	50
Start date	1 January 2019
Primary completion	1 July 2020
Estimated completion	1 July 2020
Sites	1 location across China

Drugs / interventions tested

Paclitaxel — full drug profile →

Conditions studied

Organoid — all drugs for Organoid →

Sponsor

Peking Union Medical College

Who can join

18 and older, female only, with Organoid. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single center, single arm, open and exploratory clinical study, with 50 cases planned for a period of 2 years. The purpose of this study is to evaluate the consistency and accuracy of Patient-Derived Organoid Model of breast cancer to predict the clinical efficacy of the drug, as well as the possibility of guiding the neoadjuvant chemotherapy.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Organoids: The current status and biomedical applications.
Yang S, Hu H, Kung H, Zou R, et al · · 2023 · cited 162× · PMID 37215622 · DOI 10.1002/mco2.274
Patient-Derived Organoids in Precision Medicine: Drug Screening, Organoid-on-a-Chip and Living Organoid Biobank.
Zhou Z, Cong L, Cong X. · · 2021 · cited 112× · PMID 35036354 · DOI 10.3389/fonc.2021.762184
Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology.
Thorel L, Perréard M, Florent R, Divoux J, et al · · 2024 · cited 90× · PMID 38945959 · DOI 10.1038/s12276-024-01272-5
Clinical translation of patient-derived tumour organoids- bottlenecks and strategies.
Foo MA, You M, Chan SL, Sethi G, et al · · 2022 · cited 61× · PMID 35272694 · DOI 10.1186/s40364-022-00356-6
Organoids: development and applications in disease models, drug discovery, precision medicine, and regenerative medicine.
Yao Q, Cheng S, Pan Q, Yu J, et al · · 2024 · cited 40× · PMID 39309690 · DOI 10.1002/mco2.735
S6K1 amplification confers innate resistance to CDK4/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer.
Mo H, Liu X, Xue Y, Chen H, et al · · 2022 · cited 38× · PMID 36042494 · DOI 10.1186/s12943-022-01642-5
Patient-Derived Tumor Organoids for Drug Repositioning in Cancer Care: A Promising Approach in the Era of Tailored Treatment.
Vivarelli S, Candido S, Caruso G, Falzone L, et al · · 2020 · cited 29× · PMID 33291603 · DOI 10.3390/cancers12123636
Tumour organoids and assembloids: Patient-derived cancer avatars for immunotherapy.
Mei J, Liu X, Tian HX, Chen Y, et al · · 2024 · cited 25× · PMID 38664597 · DOI 10.1002/ctm2.1656

Verify or expand the search:

Other trials of Paclitaxel

Trials testing the same drug.

NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting
NCT07195734 — Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer · Phase 2 · recruiting
NCT07465757 — A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) · Phase 2 · not yet recruiting

Other recruiting trials for Organoid

Currently open trials in the same condition.

NCT06536725 — Observation of Clinical Consistency of Organoid-chips Drug Sensitivity in Chemotherapy for PCa With Visceral Metastasis · recruiting
NCT05669586 — Organoids Predict Therapeutic Response in Patients With Multi-line Drug-resistant Lung Cancer · Phase 2 · recruiting
NCT03979170 — Patient-derived Organoids of Lung Cancer to Test Drug Response · recruiting

Other Peking Union Medical College trials

Trials by the same sponsor.

NCT05917418 — Nutritional Support on Outcomes and Cost-effectiveness for Patients at Risk · NA · not yet recruiting
NCT07261072 — Comparison of the Clinical Efficacy and Safety of Topical and Subcutaneous Injection of Secukinumab in HS · Phase 4 · not yet recruiting
NCT06026709 — Effectiveness and Cost-effectiveness of Digital Psychological Intervention (EmoEase) in Chinese COPD Patients · NA · not yet recruiting
NCT07183033 — Exploratory Trial of VR Intervention on Neuroplasticity in Older Adults With Cognitive Frailty · NA · enrolling by invitation
NCT07109765 — Secukinumab Treatment for Moderate to Severe Hidradenitis Suppurativa · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03544047 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College
Last refreshed: 11 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03544047.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing